SCYX

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Scynexis Inc. (SCYX) on Monday reported a loss of $21.3 million in its first quarter. The Jersey City, New Jersey-based company said it had a loss of 42 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCYX at https://www.zacks.com/ap/SCYX

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD) A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027 Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1st SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the third quarter of 2026; SCYNEXIS is accepting requests for granting access to oral SCY-247 via expanded access program GSK is committed to the relaunch of Brexafemme which has the potential to provide up to approximately $146 million in annual net sales milestones. SCYNEXIS ended Q1 2026 with cash, cash equivalents and investments of $72.4 million, this coupled with the approximately $16.0 million in proceeds received on April 1st extends SCYNEXIS’ cash runway to mid-2029 JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the first quarter ended March 31, 2026. “Following our recent acquisition of SCY-770, we plan to initiate a Phase 2 proof-of-concept study in ADPKD patients in Q4 2026 to demonstrate the potential of this highly differentiated molecule, which targets multiple key drivers of disease progression,” said David Angulo, M.D., President and Chief Executive Officer. “We would like to thank our existing and new investors who participated in our recent private placement financing. Combined with our existing cash position, this additional capital significantly extends our cash runway to the middle of 2029 approximately one year beyond the anticipated completion of the Phase 2 study for SCY-770.” “As we move ahead with the SCY-770 clinical program, we also continue to make progress with our second generation fungerp, SCY-247. After completion...

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026 Responding to patients’ need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026 SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2025. “In the fourth quarter, we continued to advance our second generation fungerp, SCY-247, and also strengthened our balance sheet with the receipt of $24.8 million from GSK, extending our cash runway for more than two years,” said David Angulo, M.D., President and Chief Executive Officer. “Looking ahead, SCYNEXIS remains well positioned to explore a number of opportunities to enhance shareholder value, including releasing Phase 1 data from our SCY-247 intravenous (IV) formulation study later this year.” Ibrexafungerp / GSK Update On November 19, 2025, the SCYNEXIS announced that it completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application (NDA) to GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK). GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range. On October 15, 2025, SCYNEXIS announced that it would receive a one-time non-refundable payment of $24.8 million from GSK as part of the resolution of the disagreement with GSK related to the restart of the Phase 3 MARIO study in invasive candidiasis (IC) under a binding memorandum of understanding (Binding 2025 MOU). SCYNEXIS also announced that it would promptly commence appropriate wind-down activities associated with the termination of the MARIO study. SCY-247 Development Program Update On September 2025, SCYNEXIS announced positive Phase 1 SA...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Scynexis Inc. (SCYX) on Wednesday reported profit of $12.3 million in its fourth quarter. The Jersey City, New Jersey-based company said it had profit of 25 cents per share. The pharmaceutical company posted revenue of $18.6 million in the period. For the year, the company reported a loss of $8.6 million, or 17 cents per share. Revenue was reported as $20.6 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCYX at https://www.zacks.com/ap/SCYX

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Scynexis Inc. (SCYX) on Wednesday reported a loss of $8.6 million in its third quarter. The Jersey City, New Jersey-based company said it had a loss of 17 cents per share. The pharmaceutical company posted revenue of $334,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCYX at https://www.zacks.com/ap/SCYX

SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study. Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Company aims to release clinical proof of concept data in invasive candidiasis in 2026 and is exploring non-dilutive funding opportunities to support the development of SCY-247. GSK remains committed to the relaunch of BREXAFEMME® with activities ongoing to transfer the NDA before the end of the year. Following the relaunch, SCYNEXIS stands to receive up to approximately $146 million in annual net sales milestones as well as royalties net of payments to Merck, in the low to mid single digit range. SCYNEXIS ended Q3 2025 with cash, cash equivalents and investments of $37.9 million; after receiving the one-time payments of $24.8 million from GSK in Q4 of 2025, the company’s cash runway will be greater than two years. JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2025. “Over the last several weeks, SCYNEXIS realized two significant achievements that we believe position our company for significant growth and success,” said David Angulo, M.D., President and Chief Executive Officer. “First, we announced the positive SAD/MAD data for our second-generation fungerp drug candidate, SCY-247, demonstrating that orally administered SCY-247 was well tolerated and achieved the estimated efficacy exposure at doses lower than the first generation fungerp (ibrexafungerp). We are excited about the favorable tolerability and pharmacokinetics of SCY-247 and look forward to commencing a Phase 2 study in invasive candidiasis, aiming to release proof of concept data in 2026. Secondly, we announced a successful resolution of our disagreement with GSK, which led to the one time payments of $24.8 million to SCYNEXIS which we will receive in Q4 of 2025. This...

SCYNEXIS Inc. (NASDAQ:SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS announced positive results from a Phase 1 clinical study evaluating SCY-247, its second-generation triterpenoid antifungal compound. The candidate is being developed for the treatment and prevention of invasive fungal infections to provide the therapeutic advantages of both an oral and an intravenous/IV formulation. The favorable results show orally administered SCY-247 can achieve target exposures for efficacy with favorable tolerability, and at doses lower than their first-generation fungerp, which may offer a tolerability advantage. The Phase 1 study was conducted in healthy participants to assess the safety, tolerability, and pharmacokinetics of orally administered SCY-247. SCY-247 was well tolerated across all SAD and MAD cohorts. The positive safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247. Further details from this study are expected to be presented at an upcoming scientific meeting. SCYNEXIS Inc. (NASDAQ:SCYX) is a biotechnology company that develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the US. While we acknowledge the potential of SCYX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247 JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive results from a Phase 1 study of SCY-247, its second-generation triterpenoid antifungal under development for the treatment and prevention of invasive fungal infections with the potential to provide the therapeutic advantages of both an oral and IV formulation. “We are pleased by the favorable results from this Phase 1 study demonstrating that orally administered SCY-247 can achieve target exposures for efficacy with favorable tolerability,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “We also observed that orally administered SCY-247 was able to achieve target exposures for invasive fungal disease at doses lower than our first generation fungerp, which may translate to a tolerability advantage. There remains a substantial unmet need for safe and effective, oral and intravenous antifungal agents to treat invasive fungal infections, particularly those caused by resistant fungi. The clinical data from our Phase 1 study, along with pre-clinical efficacy data generated to date, favorably position SCY-247 as a strong product candidate to meet these significant needs. We are looking forward to continuing the development of our second generation fungerp.” Phase 1 Study Description: The study evaluated the safety, tolerability and pharmacokinetics of orally administered SCY-247 in healthy participants receiving single ascending doses (SAD) ranging from 50mg to 900mg and multiple ascending doses (MAD) ranging from 50mg to 300mg, once a day for 7 days. Each dose level was evaluated in 8 participants, with 6 participants receiving SCY-247 and 2 receiving a matching placebo. A total of 66 participants received SCY-247 and 22 received placebo in the SAD and MAD cohorts. Phase 1 Study Results: SCY-247 was well tolerated across all evaluated SAD and MAD cohorts. No serious or severe treatment emergent adverse events (TEAEs) were reported. The incidence of TE...

Net loss: US$6.89m (loss narrowed by 52% from 2Q 2024). US$0.14 loss per share (improved from US$0.30 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 26%. Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 8.4% from a week ago. It's still necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with SCYNEXIS, and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments. SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (NDA) to GSK by the end of this year, ahead of anticipated GSK Regulatory interactions in 2026 to discuss the relaunch of the product. The Company anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3 2025 Regarding the November 2023 securities class action, that was filed by Brian Feldman against the Company and certain of the Company's executives in the United States District Court, District of New Jersey, the court granted the Company's motion to dismiss with leave to amend on July 30, 2025 SCYNEXIS ended Q2 2025 with cash, cash equivalents and investments of $46.5 million and projects a cash runway into Q4 2026. JERSEY CITY, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2025. “We are excited about the continued progress of our second-generation fungerp candidate, SCY-247, and we anticipate announcing SAD/MAD data from our ongoing Phase 1 study of oral SCY-247 this quarter,” said David Angulo, M.D., President and Chief Executive Officer. “We also continue to work towards resolving our dispute with GSK as it relates to the payment of the milestones associated with the restart and continuation of the MARIO study. As these discussions continue, GSK has emphasised that it remains committed to the commercialization of Brexafemme in vulvovaginal candidiasis. Per GSK’s request, we have initiated transfer of the New Drug Application for Brexafemme to them which will enable GSK to initiate regulatory interactions to discuss the relaunch of the product.” Ibrexafungerp / GSK Developments SCYNEXIS is working to transfer the BREXAFEMME NDA to GSK by the end of 2025. Once this transfer has been comp...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Scynexis Inc. (SCYX) on Wednesday reported a loss of $6.9 million in its second quarter. The Jersey City, New Jersey-based company said it had a loss of 14 cents per share. The pharmaceutical company posted revenue of $1.4 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCYX at https://www.zacks.com/ap/SCYX

Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme. Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales. Presented positive preclinical data for its second-generation fungerp candidate, SCY-247, at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) meeting; Company expects to report initial Phase 1 data for SCY-247 in Q3 2025. SCYNEXIS ended Q1 2025 with cash, cash equivalents and investments of $53.8 million and projects a cash runway into Q3 2026. JERSEY CITY, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2025. “The lifting of the clinical hold for ibrexafungerp was an important achievement for our company. While seeking to resolve the disagreement with GSK, we are moving forward with the Phase 3 MARIO study. Our second-generation fungerp candidate, SCY-247, continues to progress, with Phase 1 study results expected in the upcoming months,” said David Angulo, M.D., President and Chief Executive Officer. “SCYNEXIS remains committed to developing novel antifungal solutions to the rising threat of deadly fungal infections including invasive candidiasis for which there are limited treatment options and significant concerns for emergence of resistances, as highlighted by the WHO in their call to industry and other parties for research, development and public health action in this area of unmet need,” he added. Ibrexafungerp / GSK Developments In late April, the FDA notified SCYNEXIS that the clinical hold on ibrexafungerp had been lifted and concluded that the Phase 3 MARIO study could resume. The MARIO study is a Phase 3 trial evaluating ibrexafungerp for the treatment of invasive candidiasis. Subsequently GSK notified SCYNEXIS of their intention to immediately terminate the study. SCYNEXIS does not believe that GSK currently has the right to unilaterally terminate the MARIO study under t...